Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SPRO
#3989
Spero Therapeutics, Inc. - Common Stock
1.6
5
USD
-0.03%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-2.94%
Monthly Change
-44.07%
6 month change
-31.25%
Year Change
-33.73%
Previous Close
1.7
0
Open
1.7
1
Low
1.6
3
High
1.7
1
Volume
367
Markets
US Stock Market
Healthcare
Biotechnology
SPRO
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q1, 25
Q2, 25
Q3, 25
Q4, 25
Q1, 26
TTM
Cash from operating activities
-4 M
-17.69 M
17.42 M
-8.35 M
15.86 M
7.24 M
Cash from investing activities
—
—
—
—
—
—
Cash from financing activities
—
—
—
—
—
—
Free cash flow
-4 M
-17.69 M
17.42 M
-8.35 M
15.86 M
7.24 M
News
Spero Therapeutics: "Buy" Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO)
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO)
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO)
Keutzer, Spero Therapeutics COO, sells $44k in shares
Spero Therapeutics CEO sells $207k in stock
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook
Spero Therapeutics announces board resignation and SEC investigation closure
GSK files NDA resubmission for Spero’s tebipenem HBr antibiotic
Spero Therapeutics earnings beat by $0.26, revenue fell short of estimates